FY27 Social Impact Partnerships Act: Federal Funding Opens Path for Psychedelic Evaluation

Federal Funding Opportunity Targets Outcome-Based Social Impact Projects

The U.S. Department of the Treasury has announced a Notice of Funding Opportunity (NOFO) under the FY27 Social Impact Partnerships to Pay for Results Act (SIPPRA), as published in the Federal Register on November 12, 2026. This competitive federal program is designed to fund state and local government projects that measurably improve social outcomes, using outcome-based payment models. While the NOFO is not specific to psychedelic-assisted interventions, its focus on rigorous evaluation—including randomized controlled trials (RCTs)—creates a potential pathway for innovative behavioral health research and service delivery models involving psychedelics, provided applicants can meet the program’s stringent requirements.

Mechanism: Rigorous Evaluation and Data Standards Required

Applicants must submit a detailed evaluation design plan, limited to three pages, that addresses six core topics: outcome metrics and data sources, evaluation design and comparison group, randomization feasibility, preliminary power calculations, data access, and main risks to evaluation integrity. The evaluation must establish whether observed outcomes are attributable to the intervention, using methodologies such as RCTs, regression discontinuity, or matched comparison designs. Each metric must be independently verifiable, with clear data ownership and robust safeguards against manipulation.

Importantly, the program requires applicants to demonstrate access to necessary data—potentially including federal administrative datasets—and to secure data-use agreements and Institutional Review Board (IRB) approvals as needed. An independent evaluator, with documented experience in large-scale causal impact studies and data management, must oversee the evaluation. The evaluator’s contract must specify plans for data acquisition, management information system development, participant tracking, and compliance with federal and state data privacy standards.

• Key procedural requirements: Objective outcome metrics, rigorous evaluation design, independent evaluation, and secure, legal data access.
• Notable nuance: The requirement for independent, objective outcome metrics may limit the use of subjective self-report measures common in psychedelic research, unless paired with validated clinical endpoints or administrative data.

Policy and Research Implications for Psychedelic Projects

The SIPPRA program’s structure aligns with the growing demand for high-quality evidence in behavioral health interventions, including those involving psychedelic-assisted therapy. For the first time, psychedelic research teams may be able to access significant federal funding for real-world service delivery or demonstration projects—if they can design studies that meet the program’s rigorous standards and secure partnerships with eligible state or local government entities.

This mechanism could enable large-scale, independently evaluated trials of psychedelic interventions for conditions such as depression, post-traumatic stress disorder (PTSD), or substance use disorders, especially where outcome data can be linked to health system or administrative records. However, the need for objective, manipulation-resistant outcome measures and the requirement for independent evaluation may challenge traditional academic or clinical research models in the psychedelic field.

One non-obvious implication is that projects relying solely on patient-reported outcomes or qualitative measures may struggle to qualify unless they can supplement these with independently verifiable endpoints—such as health care utilization, employment status, or justice system involvement—tracked via administrative data. This may encourage new collaborations between psychedelic researchers, government agencies, and data custodians to design studies that satisfy both scientific and policy requirements.

Risks, Barriers, and Unknowns for Psychedelic Applicants

While the funding opportunity is significant, several risks and barriers may limit its immediate applicability to psychedelic research:

• Data access complexity: Gaining timely access to federal or state administrative datasets can be slow and legally complex, especially for sensitive health or justice data.
• Evaluation independence: The requirement for a truly independent evaluator—separate from the intervention team and funders—may complicate project governance and intellectual property considerations.
• Sample size and power: The program’s emphasis on statistical power and large sample sizes may be difficult for early-phase or niche psychedelic interventions to achieve, especially outside major urban centers.
• Regulatory uncertainty: As many psychedelic compounds remain federally controlled substances, legal and ethical approvals for large-scale implementation remain challenging, even with funding in place.

Applicants must also anticipate and mitigate risks such as participant attrition, missing data, contamination between groups, and changes in policy or service context during the study period. Failure to address these risks in the application may result in disqualification or loss of funding.

Looking Ahead: Opportunities for Strategic Collaboration

The FY27 SIPPRA funding opportunity signals a new avenue for outcome-based, government-supported evaluation of behavioral health interventions, including—but not limited to—psychedelic-assisted therapies. To capitalize, research teams will need to forge partnerships with state or local governments, secure access to objective outcome data, and design studies that meet the highest standards of causal inference and data security.

For the psychedelic field, this may catalyze a shift toward pragmatic, real-world trials that can satisfy both scientific and policy stakeholders. Success will likely depend on the ability to bridge gaps between clinical innovation, public sector priorities, and the operational demands of large-scale, independently evaluated projects.

How we research: This analysis was prepared and reviewed by Dr. Alex Kim, PhD (Policy Editor), on 2026-11-15. Primary source: U.S. Treasury Federal Register Notice (2026-22989).